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ABSTRACT: Both neurons and glia succumb to
programmed cell death (PCD) when deprived of growth
factors at critical periods in development or following
injury. Insulin-like growth factor-I (IGF-I) prevents ap-
optosis in neuronsin vitro. To investigate whether IGF-I
can protect Schwann cells (SC) from apoptosis, SC were
harvested from postnatal day 3 rats and maintained in
serum-containing media until confluency. When cells were
switched to serum-free defined media (DM) for 12–72 h,
they underwent PCD. Addition of insulin or IGF-I pre-
vented apoptosis. Bisbenzamide staining revealed nuclear
condensation and formation of apoptotic bodies in SC
grown in DM alone, but SC grown in DM plus IGF-I had
normal nuclear morphology. The phosphatidylinositol
3-kinase (PI 3-K) inhibitor LY294002 blocked IGF-I–me-
diated protection. Caspase-3 activity was rapidly activated
upon serum withdrawal in SC, and the caspase inhibitor
BAF blocked apoptosis. These results suggest that IGF-I
rescues SC from apoptosis via PI 3-K signaling which is
upstream from caspase activation. © 1999 John Wiley & Sons,
Inc. J Neurobiol 41: 540–548, 1999
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Programmed cell death (PCD) is an important mech-
anism for regulating cell numbers in the developing
nervous system. Many more cells are produced than
are needed in the adult organism. The overabundant
cells are eliminated as they compete for a limited
supply of trophic factor during critical periods of
development (Oppenheim, 1991). Glial cell line–
derived neurotrophic factor (GDNF) rescues spinal
motor neurons from naturally occurring PCD, without
which a greater proportion will die (Oppenheim et al.,
1995). Similarly, platelet-derived growth factor
(PDGF) promotes survival of developing oligoden-
drocytes (Barres et al., 1992). Astrocytes undergo
PCD during cerebellar development, which may be
regulated by a supply of some yet unknown growth
factor (Krueger et al., 1995). Schwann cells (SC), the
glia that form myelin in the peripheral nervous system
(PNS), are susceptible to PCD during critical periods
of development, a process that is likely controlled by
growth factors (Grinspan et al., 1996; Nakao et al.,
1997; Syroid et al., 1996).
A number of growth factors influence SC develop-
ment and death, including neuregulins, (NRG), trans-
forming growth factor-b (TGF-b), fibroblast growth
factor (FGF), PDGF, and insulin-like growth factor-I
(IGF-I) (Cheng et al., 1999; Dong et al., 1995; Ec-
cleston et al., 1993; Gavrilovic et al., 1995; Kopp et
al., 1997; Marushige and Marushige, 1994; Shaw et
al., 1997; Skoff et al., 1998; Syroid et al., 1996) (for
review, see Scherer and Salzer, 1996). SC express
receptors for these trophic factors, including the
PDGF and NRG receptors, and the type-I IGF recep-
tor (IGF-IR) (Carroll et al., 1997; Eccleston et al.,
1993; Grinspan et al., 1996; Leventhal et al., 1995).
SC express IGF-IR and make IGF-I during critical
periods of development (Cheng et al., 1996; D’Ercole
et al., 1996) when PCD is occurring. However, the
mechanisms responsible for governing SC response to
IGF-I are relatively poorly understood.
We have demonstrated the pluripotent actions of
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IGF-I on SH-SY5Y neuroblastoma cells, dorsal root
ganglia neurons, and SCin vitro. IGF-I promotes
motility in SC, an important attribute for proper my-
elination of developing axons (Cheng et al., 1999).
Similarly, IGF-I promotes motility in neurons (Kim
and Feldman, 1998; Kim et al., 1997; Leventhal and
Feldman, 1997; Leventhal et al., 1997) and serves as
a protective agent against apoptosis in SH-SY5Y cells
and sensory neurons (Cheng and Feldman, 1998; Mat-
thews and Feldman, 1996; Matthews et al., 1997;
Russell et al., 1998; Singleton et al., 1996a,b).
The aim of the current study was to examine
whether and how IGF-I prevents apoptosis in SC. We
report that SC grown in serum-free defined media
undergo apoptosis. Insulin or especially IGF-I added
to the defined media is protective. PI 3-kinase inhib-
itors block the protective effect of IGF-I. Caspase
inhibitor either alone or in conjunction with PI 3-ki-
nase inhibitor prevents apoptosis, suggesting that
caspases function downstream from PI 3-kinase.
Hence, IGF-I, signaling predominantly via the PI
3-kinase, protects SC from caspase-mediated apopto-
sis induced by serum withdrawal.
MATERIALS AND METHODS
Reagents
Tissue culture plates were obtained from Corning (Corning,
NY). Dulbecco’s modified Eagle’s medium (DMEM), low-
glucose DMEM, Ham’s F-12, calf serum (CS), fetal bovine
serum (FBS), trypsin–ethylenediaminetetraacetic acid
(EDTA), pituitary extract, and Hank’s balanced salt solution
(HBSS) were purchased from Gibco-BRL (Gaithersburg,
MD). Recombinant human IGF-I was a generous gift of
Cephalon (West Chester, PA) and was stored at 100 mM in
acetic acid at280°C until use. Caspase-3 fluorometric
assay kit was purchased from Pharmingen (San Diego, CA).
The caspase inhibitor bok-asp-fmk (BAF) (50mM) was a
gift from Dr. Brenda Shivers of Parke-Davis Pharmaceutical
Research (Ann Arbor, MI). The MEK inhibitor PD98059
(10 mM) and the PI 3-K inhibitor LY294002 (10mM) were
purchased from Biomol (Plymouth Meeting, PA). All other
chemicals were purchased from Sigma Chemical Company
(St. Louis, MO). Culture dishes and coverslips were coated
with 0.001% poly-L-lysine prior to use.
Collection of SC
Schwann cells were harvested from sciatic nerves of post-
natal day 3 Sprague-Dawley rats (Harlan-Sprague Dawley,
Indianapolis, IN) as described previously (Brockes et al.,
1980; Cheng et al., 1999). Cells were maintained in growth
media (GM) of DMEM, 10% FBS, 2mM forskolin, and 10
mg/mL bovine pituitary extract. Cells were passaged upon
confluency (1:4) and used for experiments for four passages.
At the beginning of each experiment, cells were washed
twice with HBSS and cultured in a serum-free defined
media (DM) [low glucose DMEM/Ham’s F-12 1:1, trans-
ferrin (10 mg/mL), putrescine (10mM), progesterone (20
nM), and sodium selenite (30 nM)].
Nuclear Staining
Schwann cells were grown in DM6 10 nM IGF-I for 24 h
and fixed with 10% formalin in phosphate-buffered saline
(PBS) (pH 7.4) for 30 min. SC were stained with bisbenz-
amide (1 mg/mL in PBS) for 15 min, rinsed with PBS,
mounted with Gel/Mount (Fort Washington, PA), and
viewed under ultraviolet (UV) illumination on a Nikon
Microphot fluorescence microscope (Matthews and Feld-
man, 1996).
Flow Cytometry
DNA fragmentation is a hallmark of apoptosis. The DNA
fragments are multiples of 180–200 base pairs and are
present in the sub G0 region of DNA content histograms.
Flow cytometry is used to determine the cell-cycle phase
distribution and quantitate the percentage of cells in sub-G0
as a measure of apoptosis (Kokileva, 1994; Matthews et al.,
1997; Sgonc and Wick, 1994). Briefly, after cells were
cultured in DM for the appointed times, the culture media
and trypsized cells were combined and washed twice in
HBSS. Single-cell suspensions were fixed in ice-cold 70%
ethanol and stored up to 1 week at 4°C. Fixed cells were
rinsed twice with HBSS and stained with propidium iodide
(18 mg/mL) for 1–4 h. Flow cytometry data were collected
from an Epics Elite flow cytometry system (Coulter Cytom-
etry, Hialeah, FL).
Caspase Fluorometric Assay
Caspase-3 fluorogenic assay was conducted according to the
manufacturer’s instructions. Briefly, media and trypsinized
cells were collected and washed twice with PBS. Next, 2
3 105 cells in 500mL PBS were added to 10mL (10 mg)
Ac-DEVD-AMC (fluorogenic substrate) and incubated at
37°C for 1 h. The fluorescence emitted by cleaved substrate
was measured on an Epics Elite flow cytometry system
(Coulter Cytometry, Hialeah, FL) using UV excitation (440
nm).
RESULTS
Previous reports demonstrate SC undergo apoptosisin
vivo both during development and following injury
and disease (Berciano et al., 1998; Erdem et al., 1998;
Jessen et al., 1994; Nakao et al., 1997; Syroid et al.,
1996; Trachtenberg and Thompson et al., 1996). Sy-
roid et al. (1996) examined SC apoptosisin vitro
following serum withdrawal. To develop ani vitro
system to investigate the intracellular signaling mech-
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anisms of SC undergoing apoptosis, we employed a
similar serum withdrawal paradigm.
Apoptosis Following Serum Withdrawal
Schwann cells were cultured in serum-free DM for
12, 24, 48, or 72 h, and processed for FACS analysis.
Cells in the sub-G0 region of the DNA content histo-
grams were considered apoptotic. At 12 h, 146 2%
of SC were apoptotic, increasing to 576 5% by 72 h
[Fig. 1(A)]. Control cultures maintained in standard
GM containing serum (see Materials) exhibited a
baseline of 5–10% apoptosis at any given time in
culture (data not shown). Hence, in SC cultures
switched from GM to DM, the proportion of cells that
underwent apoptosis increased with time, suggesting
that factors in the GM were critical for survival. There
was a marked increase in apoptosis at 24 h. Cells were
grown for 24 h in DM for further experiments unless
otherwise noted.
Serum Blocks Apoptosis
Because GM contains essential components, we cul-
tured SC in DM with increasing concentrations of
FBS. Relatively low concentrations of serum, 0.3%
and 1.0%, were able to rescue apoptotic cells, and
3.0% and 10% FBS improved on this effect [Fig.
1(B)]. The percentage of apoptotic cells grown in DM
plus either 3% or 10% (96 1.7% and 66 0.8%
apoptotic, respectively) was similar to those grown in
GM. Serum added to DM was sufficient to protect
against apoptosis.
Insulin or IGF-I Prevents Apoptosis
There are several reports in the literature in which SC
were grown in serum-free DM (Dong et al., 1995;
Jessen et al., 1994; Stewart et al., 1996). The main
difference between these reports and our DM is the
inclusion of insulin, IGF-I, or both (Dong et al., 1995;
Jessen et al., 1994; Stewart et al., 1996). To examine
whether either of these is sufficient to protect against
apoptosis induced by serum withdrawal, SC were
cultured for 24 h in DM with the addition of either
insulin or IGF-I to the culture media in dose ranges
representative of those published concentrations. Fig-
ure 2(A) shows that insulin offers some protection
from apoptosis in 24 h at higher concentrations (18.8
6 2.24% at 1000 ng/mL media or 174mM) compared
to DM alone (35.36 2.22%). In contrast, IGF-I was
extremely protective in doses as low as 0.3 nM (15.95
6 3.7%) compared to DM alone (36.86 5.52%). It is
likely that these components were responsible for
maintaining healthy SCin vitro in those early studies
(Dong et al., 1995; Jessen et al., 1994; Stewart et al.,
1996). Thus, SC undergo apoptosis following serum
withdrawal, and IGF-I is highly protective.
Apoptotic Morphology
To examine nuclear morphology, SC were cultured in
DM 6 10 nM IGF-I for 24 h and stained with bis-
benzamide. SC grown in DM plus IGF-I had evenly
stained, healthy nuclei [Fig. 3(B)]. There were few if
any pyknotic nuclei. In contrast, SC grown in DM
alone were less dense, probably because a portion of
the population had already died and detached from the
plate. Some of the cells that remained attached were
in a slightly different plane of focus, suggesting they
were beginning to detach. These SC displayed apo-
ptotic morphology; the nucleus had condensed and
formed small apoptotic clusters [Fig. 3(A)].
Figure 1 Serum withdrawal induced apoptosis in SC
grown in defined media. SC were grown until confluency in
GM and then switched to serum-free DM for 12, 24, 48, or
72 h (A). Cells began to become apoptotic as early as 12 h
postserum withdrawal, and this percentage continued to
increase until 72 h, the latest time examined. When SC were
maintained in DM with the addition of increasing concen-
trations of serum for 24 h (B), they were rescued from
apoptosis.
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IGF-I Prevents Apoptosis via
PI 3-K Signaling
Previous work done in our laboratory with SH-SY5Y
neuroblastoma cells suggested that the protective ef-
fect of IGF-I is mediated via the phosphatidylinositol
3-kinase (PI 3-K) as opposed to the MAP kinase
pathway (Singleton et al., 1996a). To examine this
signaling pathway, SC were cultured for 24 h in DM
alone, and with or without IGF-I (10 nM), the PI 3-K
inhibitor LY294002 (10mM), and the MAP kinase
inhibitor PD98059 (10mM) (Fig. 4). Twenty-five
percent of the SC were apoptotic when grown in DM
alone or either inhibitor. IGF-I decreased the number
of apoptotic cells to only 12.9%. LY294002 blocked
IGF-I’s protective effect (22.0% apoptosis), but
PD98059 did not (only 13.2% apoptotic cells). This
demonstrates that IGF-I mediates its protection in SC
predominantly via the PI 3-K.
Caspases in SC Apoptosis
Caspases act as downstream effector molecules in
many models of cell death (Thornberry and Lazebnik,
1998). To determine whether caspases are active dur-
ing SC apoptosis, we initiated apoptosis by withdraw-
ing serum and cultured SC in DM alone, with IGF-I,
or with the caspase inhibitor BAF (50mM) (Fig. 5).
BAF protected SC from apoptosis. Furthermore, when
SC were grown with both IGF-I and BAF, or
LY294002 (10mM) and BAF, the percent apoptotic
cells was still about 10%. BAF was not additive to
IGF-I’s protection and was not blocked by PI 3-K
inhibition, suggesting that caspase activation was
downstream from both IGF-I signaling and PI 3-K
activity.
Caspases-3-like Activation in SC
Considering the neurologic phenotype of the caspase-
3-null mouse, in which the developing brain lacks
appropriately timed apoptosis, causing a variety of
hyperplasias (Kuida et al., 1996), it seemed possible
Figure 2 Insulin and IGF-I are essential components in
DM formulations. SC were grown in DM plus either insulin
(A) or IGF-I (B) for 24 h. Relatively high concentrations of
insulin (1000 ng/mL) were required to prevent apoptosis,
whereas smaller amounts of IGF-I (0.3 nM) were effective
in reducing apoptosis in SC.
Figure 3 SC undergoing apoptosis displayed typical apo-
ptotic morphology. SC grown in DM for 24 h developed
morphologic manifestations of apoptosis. Staining with bis-
benzamide displayed chromatin condensation and nuclear
fragmentation [(A), arrow]. SC grown in DM with 10 nM
IGF-I for 24 h had healthy, evenly stained nuclei (B).
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that caspase-3 plays an active role in SC apoptosis.
However, we were unable to identify the cleaved
product by immunoblotting of whole cell lysate from
apoptotic SC (data not shown). As an alternative, a
more sensitive fluorometric technique was employed
to measure caspase-3 activity. In this assay, activated
caspase-3 and caspase-7 cleaved a fluorogenic sub-
strate, and the resulting fluorescence was measured by
flow cytometry. SC were cultured in DM with or
without IGF-I. In SC cultures grown in DM alone for
1 h, there was a slight increase in fluorescence com-
pared to the control nonapoptotic population (Fig. 6).
This difference between the DM alone and control
was greatest at 3 h, when 44.2% of cells had activated
caspase. At 6 h, this effect decreased to 5.5% of cells,
and even further to 2.7% at 12 h (Fig. 6). At all time
points, the addition of IGF-I decreased caspase-3 ac-
tivation.
DISCUSSION
Our laboratory has established that IGF-I exerts mul-
tiple affects on cells of the nervous system, including
promoting neurite outgrowth (Kim et al., 1997; 1998),
inducing cytoskeletal rearrangement (Kim and Feld-
man, 1998; Leventhal and Feldman, 1997; Leventhal
et al., 1997), and protecting cells from programmed
cell death (Cheng and Feldman, 1998; Singleton et al.,
1996a,b) (for review, see Feldman et al., 1997). SH-
SY5Y cells undergo hyperosmotic-induced PCD, ex-
hibiting nuclear fragmentation and DNA laddering
(Matthews and Feldman, 1996; Matthews et al.,
1997). IGF-I protects the cells from apoptosis via the
type I IGF receptor (Singleton et al., 1996a,b). Cur-
rent investigations extended this line of inquiry to SC,
the myelinating cells of the peripheral nervous sys-
tem.
Schwann cells grown in serum-containing media
underwent apoptosis when switched to serum-free
DM. Insulin and particularly IGF-I were effective in
preventing this induction of apoptosis. Our results
were in agreement with a recent report by Syroid et al.
(1999), in which IGF-I promoted survival of postnatal
Figure 4 IGF-I signals via PI 3-K. SC were grown in DM
for 24 h, with or without the PI 3-K inhibitor LY294002 (10
mM) (1LY), the MAP kinase inhibitor PD98059 (10mM)
(1PD), and IGF-I. Neither the LY nor the PD inhibitors had
an influence on SC apoptosis compared to DM alone. IGF-I
(10 nM) rescued SC from apoptosis, and LY294002 inter-
fered with the ability of IGF-I to prevent PCD. PD98059
slightly diminished the protective effect of IGF-I.
Figure 5 Caspase inhibition prevented apoptosis in SC.
SC were grown in DM for 24 h, alone (DM), plus IGF-I (10
nM), plus the caspase inhibitor bok-asp-fmk (50mM)
(1BAF), plus BAF and the PI 3-K inhibitor LY294002 (10
mM) (1BAF 1LY), or plus BAF and the MAP kinase
inhibitor PD98059 (10mM) (1BAF 1PD). Both IGF-I and
BAF were protective. Neither the LY nor the PD interfered
with the protective effect of BAF.
Figure 6 Caspase-3 was rapidly activated in SC apoptosis.
SC were grown in DM6 IGF-I (10 nM) for 1, 3, 6, or 12 h.
Fluorogenic substrate was cleaved as caspase-3 was acti-
vated. Percent cells fluorescent is an indication of caspase
activation. Caspase-3 was activated as early as 1 h post-
serum withdrawal, peaked at 3 h, and decreased at 6 and
12 h. At each time point, the inclusion of IGF-I diminished
caspase-3 activation.
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SC grownin vitro in DM for up to 3 days. In these
experiments, cell survival was measured using the
MTT assay as an indicator of SC viability. In the
current studies, IGF-I rescued mainly via the PI 3-K
pathway and prevented caspase activation which rap-
idly occurred following serum withdrawal. These
findings concur with our previous reports for SH-
SY5Y cells (Matthews and Feldman, 1996; Matthews
et al., 1997; Singleton et al., 1996a). The replication
of these findings in SC is of particular interest because
of the important role that SC play as the myelinating
cells of the peripheral nervous system.
Our findings indicate that serum withdrawal in-
duced PCD in cultured SC beginning as early as 12 h
and increasing to 72 h, at which time the majority of
cells were dead or detached from the plate. Bisbenz-
amide staining revealed nuclear condensation charac-
teristic of apoptotic cells. Syroid et al. (1996) made
similar observations. Following serum withdrawal,
they noted chromatin condensation and TUNEL-pos-
itive cells. Interestingly, neither we (data not shown)
nor Syroid et al. (1996) were able to identify DNA
laddering in SC.
This evidence of SC apoptosisin vitro reflects the
apoptosis that is naturally occurringin vivo. Compe-
tition for axonal-derived growth factors such as NRG
control the survival of SC during neonatal and early
postnatal development in the rat (Grinspan et al.,
1996; Nakao et al., 1997; Syroid et al., 1996). SC
death by apoptosis is well documented following
nerve injury (Ekstrom, 1995; Grinspan et al., 1996;
Kopp et al., 1997; Syroid et al., 1996; Trachtenberg
and Thompson, 1996; Zorick and Lemke, 1996) and is
apparent in tellurium-induced neuropathy (Berciano
et al., 1998) as well as Charcot–Marie–Tooth neurop-
athy (Erdem et al., 1998), a hereditary disorder in
humans. Considering the integral role of SC apoptosis
in normal development, experimental neuropathies,
and human disease, ani vitro model is required so
that death mechanisms may be more fully understood
at the molecular and biochemical levels.
The data indicate that IGF-I prevents apoptosis
predominantly through activation of the PI 3-K. We
cannot rule out a role for the MEK pathway, however,
since the MEK inhibitor PD98059 causes a small
diminution of IGF-I’s ability to rescue SC from PCD.
Recent studies suggest a link between PI 3-K and
protection from PCD in hematopoietic cells and fi-
broblasts (Minshall et al., 1996; Yao and Cooper,
1996). Concentrations of insulin which are known to
activate IGF-IR (De Meyts et al., 1994) prevent PCD
in PC12 cells by activating PI 3-K, independent of the
MEK pathway (Yao and Cooper, 1995). In parallel,
the ability of insulin to prevent PCD in PC12 cells is
blocked by wortmannin, a specific inhibitor of PI 3-K
(Yao and Cooper, 1995). IGF-I signaling may follow
a linear pathway in apoptotic prevention through the
IGF-IR, PI 3-K, Akt, and Bad (Datta et al., 1997; del
Peso et al., 1997; Dudek et al., 1997; Kauffmann-Zeh
et al., 1997; Kennedy et al., 1997; Kulik et al., 1997;
Kulik and Weber, 1998; Zhang et al., 1998). Our own
studies in SH-SY5Y cells indicated that IGF-I pre-
vents PCD via the IGF-IR:PI 3-K pathway (Singleton
et al., 1996a). Collectively, previous reports (see
above references), our own work in SH-SY5Y cells
(Singleton et al., 1996a), and the results from SC
presented here support the theory that activation of
IGF-IR by IGF-I prevents PCD via a PI 3-K signaling
pathway.
A number of pro- and anti-apoptotic proteins are
involved in the apoptotic pathway (for reviews, see
Adams and Cory, 1998; Ashkenazi and Dixit, 1998;
Evan and Littlewood, 1998; Green and Reed, 1990).
Caspases are almost universally implicated in apopto-
sis (Thornberry and Lazebnik, 1998). Recent reports
in neuronal cells suggest caspases are activated early
in the death cycle, followed later by morphological
and biochemical evidence of DNA fragmentation
(Posmantur et al., 1997). In the current study, we
show that caspases are involved in SC apoptosis.
Caspase-3–like activity rapidly increases following
serum withdrawal, and a caspase inhibitor prevents
apoptosis. Increased caspase activity is detected early,
followed by later morphological evidence of SC ap-
optosis (i.e., bisbenzamide staining). That IGF-I de-
creases caspase-3–like activity following serum with-
drawal in SC is in accordance with our own findings
in SH-SY5Y cells and DRG neurons (Singleton et al.,
1996a; Russell et al., 1998) and reports in cerebellar
granule neurons (Tanabe et al., 1998; Tanaka et al.,
1998), hypoxic cortical neurons (Tamatani et al.,
1998), and cardiomyocytes (Wang et al., 1998a,b).
In addition to IGF-I, several growth factors includ-
ing NGF, BDNF, NT-3, NT-4/5, LIF, CNTF, TGF-b,
GDNF, and the neuregulins (NRG) may play support-
ing roles in SC development, migration, and survival
(for review, see Scherer and Salzer, 1996). The NRG
are a group of peptide growth factors that are the
product of alternative splicing from a single gene
(Marchionni et al., 1993). They exert their biological
effects through the EGF-like erbB2, 3, and 4 receptors
(reviewed by Marchionni et al., 1997). Significantly,
SC express the erbB receptors at critical periods of SC
apoptosis during development and following injury
(Carroll et al., 1997; Grinspan et al., 1996). NRG
prevents apoptosis of SC during development (Dong
et al., 1996; Grinspan et al., 1996) and following
injury (Carroll et al., 1997; Grinspan et al., 1996;
Kopp et al., 1997; Trachtenberg and Thompson,
1996). Indeed, NRG promotes SC motility and neurite
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outgrowth (Mahanthappa et al., 1996), findings reca-
pitulated in our laboratory with IGF-I (Cheng et al.,
1999). NRG protects against apoptosis following se-
rum-withdrawal in SC (Li et al., 1998). Clearly, IGF-I
and NRG have overlapping functionsin vivo and in
vitro, and how these may relate to one another has not
been investigated.
In conclusion, IGF-I, signaling via the PI 3-K,
rescues SC from caspase-mediated apoptosis follow-
ing serum withdrawal. Our results in SC largely du-
plicate those reported for neurons, emphasizing the
need to determine the details of the apoptotic machin-
ery in each cell type of clinical relevance. It is invalid
to compare SC to cancer cells, and for the same
reason an SC (or other glia) is functionally different
from a neuron. SC retain the ability to divide in the
adult; neurons are terminally differentiated and do not
divide (Korr et al., 1986; McCarthy and Leblond,
1998). In fact, glia are noted for becoming reactive
following insults, producing growth factors and re-
sponding to cytokines (Ridet et al., 1997). Our long-
term goal is to understand the continuum between
proliferation and apoptosis in glial cells and the ther-
apeutic value of growth factors such as IGF-I and
NRG in the treatment of glial cell disorders.
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